Alec Stranahan
Stock Analyst at B of A Securities
(0.71)
# 4,172
Out of 5,238 analysts
29
Total ratings
40.91%
Success rate
-40.69%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Alec Stranahan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| WVE Wave Life Sciences | Maintains: Buy | $38 → $21 | $7.18 | +192.48% | 1 | Mar 27, 2026 | |
| KRYS Krystal Biotech | Maintains: Buy | $288 → $318 | $305.71 | +4.02% | 6 | Jan 22, 2026 | |
| CADL Candel Therapeutics | Downgrades: Neutral | $13 → $7 | $8.35 | -16.17% | 2 | Sep 3, 2025 | |
| XNCR Xencor | Downgrades: Neutral | $23 → $12 | $12.86 | -6.69% | 2 | Sep 3, 2025 | |
| ERAS Erasca | Downgrades: Underperform | $4 → $1 | $10.12 | -90.12% | 3 | Sep 3, 2025 | |
| NVAX Novavax | Downgrades: Underperform | $9 → $7 | $10.11 | -30.76% | 5 | Aug 20, 2025 | |
| BEAM Beam Therapeutics | Upgrades: Buy | $42 | $32.32 | +29.95% | 1 | Mar 28, 2025 | |
| CRBU Caribou Biosciences | Maintains: Buy | $13 → $11 | $1.94 | +467.01% | 1 | Jan 7, 2025 | |
| CATX Perspective Therapeutics | Downgrades: Neutral | $24 → $6 | $3.76 | +59.57% | 2 | Nov 25, 2024 | |
| EDIT Editas Medicine | Upgrades: Buy | $13 → $15 | $3.11 | +382.32% | 1 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $48 → $55 | $141.81 | -61.22% | 3 | Jul 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $5 → $6 | $42.86 | -86.00% | 2 | Dec 29, 2022 |
Wave Life Sciences
Mar 27, 2026
Maintains: Buy
Price Target: $38 → $21
Current: $7.18
Upside: +192.48%
Krystal Biotech
Jan 22, 2026
Maintains: Buy
Price Target: $288 → $318
Current: $305.71
Upside: +4.02%
Candel Therapeutics
Sep 3, 2025
Downgrades: Neutral
Price Target: $13 → $7
Current: $8.35
Upside: -16.17%
Xencor
Sep 3, 2025
Downgrades: Neutral
Price Target: $23 → $12
Current: $12.86
Upside: -6.69%
Erasca
Sep 3, 2025
Downgrades: Underperform
Price Target: $4 → $1
Current: $10.12
Upside: -90.12%
Novavax
Aug 20, 2025
Downgrades: Underperform
Price Target: $9 → $7
Current: $10.11
Upside: -30.76%
Beam Therapeutics
Mar 28, 2025
Upgrades: Buy
Price Target: $42
Current: $32.32
Upside: +29.95%
Caribou Biosciences
Jan 7, 2025
Maintains: Buy
Price Target: $13 → $11
Current: $1.94
Upside: +467.01%
Perspective Therapeutics
Nov 25, 2024
Downgrades: Neutral
Price Target: $24 → $6
Current: $3.76
Upside: +59.57%
Editas Medicine
Aug 8, 2024
Upgrades: Buy
Price Target: $13 → $15
Current: $3.11
Upside: +382.32%
Jul 16, 2024
Maintains: Buy
Price Target: $48 → $55
Current: $141.81
Upside: -61.22%
Dec 29, 2022
Maintains: Underperform
Price Target: $5 → $6
Current: $42.86
Upside: -86.00%